SEC Comment Letter 0000000000-24-013004 to Abivax S.A. (ABVX) (CIK 0001956827) (ABVX)
Abivax S.A. (ABVX) (CIK 0001956827)
Date: Nov. 22, 2024 · CIK: 0001956827 · Accession: 0000000000-24-013004
AI Filing Summary & Sentiment
File numbers found in text: 333-283336
Letter
November 22, 2024 Marc de Garidel Chief Executive Officer Abivax S.A. 7-11 boulevard Haussmann 76009 Paris France Re:Abivax S.A. Registration Statement on Form F-3 Filed November 19, 2024 File No. 333-283336 Dear Marc de Garidel: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Lauren Hamill at 303-844-1008 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Minkyu Park
Show Raw Text
November 22, 2024
Marc de Garidel
Chief Executive Officer
Abivax S.A.
7-11 boulevard Haussmann
76009 Paris
France
Re:Abivax S.A.
Registration Statement on Form F-3
Filed November 19, 2024
File No. 333-283336
Dear Marc de Garidel:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Lauren Hamill at 303-844-1008 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Minkyu Park